[Disclosure] Celltrion (068270) Submits Phase 3 Clinical Trial IND Application to U.S. FDA for ‘CT-P51 (Keytruda Biosimilar)’

Fact Source: Financial Supervisory Service (DART) / 2024-06-17

Disclosure Type: Major Management Matters Related to Investment Decisions

💡 3-Second Summary

Celltrion has submitted an Investigational New Drug (IND) application to the U.S. FDA for a global Phase 3 clinical trial of ‘CT-P51,’ a biosimilar of the reference drug Keytruda, targeting non-small cell lung cancer.

📊 1. [Summary of Core Disclosure Content and Major Figures]

• Clinical Trial Title: A randomized, double-blind, active-controlled, Phase 3 clinical trial to compare the efficacy and safety of CT-P51 and Keytruda in patients with previously untreated metastatic non-squamous non-small cell lung cancer.
• Clinical Trial Phase & Registration Number: Global Phase 3 trial / EU CT number: 2024-514048-98-00
• Target Disease (Indication): Non-small cell lung cancer (Non-Small Cell Lung Cancer)
• Submission Date & Regulator: June 14, 2024 (local time) / U.S. Food and Drug Administration (FDA)
• Trial Objective: To compare the efficacy and safety of CT-P51 and Keytruda to demonstrate biosimilarity.
• Clinical Trial Design and Scale:
  • Total Patients: 606 subjects
  • Treatment Duration: 2 years
  • Study Design: Double-blind, randomized, active-controlled, Phase 3 clinical trial.
• Future Plans and Expected Outcomes: Celltrion plans to demonstrate biosimilarity to the reference drug Keytruda through this Phase 3 trial. The company expects to expand its market and increase revenue by securing marketing approval for all approved indications of the reference drug, including other types of non-small cell lung cancer in addition to metastatic non-squamous non-small cell lung cancer.

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

• Submission of Phase 3 Trial Plan: This filing indicates that Celltrion has officially submitted its global Phase 3 clinical trial plan for CT-P51 to the U.S. FDA, initiating the administrative approval process.
• Indication Expansion and Sales Targets: As specified in the disclosure, the company’s objective is to secure marketing authorization for all approved indications of the reference drug, beyond metastatic non-squamous non-small cell lung cancer, to expand its market and increase revenue.
• Statistical Probability of Approval and Risks: According to the cautionary statements in the disclosure, the statistical probability of an investigational drug receiving final marketing approval is approximately 10%. In the event of outcomes falling short of expectations, there remains a possibility that the company may modify or abandon its commercialization plans.
• No Financial Impact or Causes Specified: This filing covers the initial application for the clinical trial plan. The disclosure does not specify any financial changes or direct causes of financial performance.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion’s latest disclosure confirms the submission of a Phase 3 clinical trial plan to the U.S. FDA for ‘CT-P51,’ a biosimilar candidate of Keytruda. The stated goal of this trial is to evaluate the efficacy and safety of CT-P51 in comparison with the reference drug to establish biosimilarity, and subsequently obtain marketing approvals across all indications held by the reference drug to drive market expansion and revenue growth.

However, investors must note that the submission of a trial plan does not guarantee final marketing approval or ultimate commercial success. As explicitly stated in the disclosure, the statistical probability of an investigational drug reaching final approval is approximately 10%, and there remains a possibility of modifying or cancelling commercialization plans. Consequently, investors should focus on verifiable milestones, starting with whether the U.S. FDA approves the clinical trial application.

📢 Disclaimer & Source Information

Source: This content was restructured and newly drafted based on the official submitted data from the Financial Supervisory Service (DART).

Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the individual investor.

Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.